Ablynx books success with arthritis drug study
BRUSSELS (Reuters) - Belgian biotech firm Ablynx said a clinical study of its rheumatoid arthritis drug ALX-0061 showed promising results and it was now considering how to further develop the drug, including a partnership deal with a bigger company.
"We are now investigating the various possibilities through which we can progress the development of ALX-0061, including discussions with potential partners and other paths which will allow us to maximise the value of this asset," Chief Executive Edwin Moses said in a statement on Wednesday.
Ablynx had carried out the study on 37 patients over the course of 24 weeks and said the drug was well-tolerated and showed positive results.
(Reporting by Robert-Jan Bartunek; editing by Philip Blenkinsop)
- Search for Malaysian plane may extend to Indian Ocean - U.S |
- Russia holds war games near Ukraine; Merkel warns of catastrophe |
- New York City gas explosion subject of federal probe |
- White House tried to mediate dispute between Senate, CIA panel: source
- UPDATE 1-U.S. investigators suspect missing Malaysian plane flew for hours -WSJ